Commercial Moberg Pharma joins hands with Allderma to market nail...

Moberg Pharma joins hands with Allderma to market nail fungus product in Scandinavia

-

Moberg pharma joins hands with Allderma to enter the market with a new nail fungus product named MOB-015.

Moberg Pharma will cover the manufacturing and delivery of the nail fungus product, while its partner will undertake the tasks of marketing the drug, completing its sale as well as distribution. The Moberg Pharma collaboration with Allderma is set to launch in Scandinavia.

The agreement between the two parties contains financial terms which are market-based and builds upon the licensing agreement the company already acquired. Allderma has had success with launching nail fungus products before as well. An example of such a product is Nalox, another Moberg Pharma collaboration with Allderma.

A Moberg official stated that the company would like to repeat the success of Nalox, which had seen a growth rate of 400% in a similar region. In fact, MOB-015 shows even more promise than Nalox.

As Allderma launches the nail product in Scandinavia, an official from the company detailed its unique features. MOB-15 is earliest in the market for this kind of topical antifungal medicine that does not pose a threat for significant side effects, and boasts an efficacy equal to oral drugs for the same purpose.

Avatar
+ posts

Latest news

Novo Nordisk Set to Slash Victoza Production to Boost Ozempic Supply

In response to the escalating demand for its GLP-1 weight loss products, Novo Nordisk is adopting a...

Merck to Purchase Caraway Therapeutics For Over $600M

Merck & Co. has openly expressed its continuous pursuit of acquisitions, and currently, the prominent pharmaceutical company...

NanoString Faces Setback in Patent Infringement Case Against Genomics

In a recent legal skirmish in the biotechnology sector, NanoString finds itself on the losing end of...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you